Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 10 years of age or older~* Executed informed consent~* Documented diagnosis of HAE (Type I or II)~* Presentation at the site within 8 hours of patient recognition of an moderate to severe HAE acute attack~Exclusion Criteria:~* Receipt of an investigational drug or device, within 30 days prior to study treatment~* Receipt of non-investigational C1-INH within 7 days of treatment~* Receipt of DX-88 (ecallantide) within 3 days prior to study treatment~* Diagnosis of acquired angioedema (AAE), estrogen-dependent angioedema or drug-induced angioedema (including angiotensin-converting enzyme inhibitor induced angioedema)~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DX-88 (ecallantide) (Type: EXPERIMENTAL): DX-88 (ecallantide) 30 mg given as three 10 mg/mL subcutaneous injections.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, Phosphate Buffer Saline (PBS), pH 7.0 given as 3 subcutaneous injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).